Advanced Search
WANG Ganggang, WANG Xianhuo, ZHANG Huilai. Research Progress on Molecular Diagnosis and Individualized Treatment for Malignant Lymphoma[J]. Cancer Research on Prevention and Treatment, 2023, 50(12): 1165-1173. DOI: 10.3971/j.issn.1000-8578.2023.23.0901
Citation: WANG Ganggang, WANG Xianhuo, ZHANG Huilai. Research Progress on Molecular Diagnosis and Individualized Treatment for Malignant Lymphoma[J]. Cancer Research on Prevention and Treatment, 2023, 50(12): 1165-1173. DOI: 10.3971/j.issn.1000-8578.2023.23.0901

Research Progress on Molecular Diagnosis and Individualized Treatment for Malignant Lymphoma

Funding: 

Tianjin Key Medical Discipline (Specialty) Construction Project TJYXZDXK-009A

More Information
  • Corresponding author:

    ZHANG Huilai, E-mail: zhlwgq@126.com

  • Received Date: August 22, 2023
  • Revised Date: September 17, 2023
  • Available Online: January 12, 2024
  • Lymphoma refers to a group of heterogeneous malignancies originating from the reticuloendothelial and lymphatic systems. The clinical manifestations, treatment strategies, and disease outcomes of different types of lymphoma considerably vary. Recent developments in high-throughput sequencing technologies have enhanced understanding of the pathogenesis and molecular stratification of lymphoma. In the era of new drugs, precise stratification and targeted drug selection can not only improve the prognosis of patients with lymphoma but also reduce the toxic side effects of traditional chemotherapy, ultimately achieving the accurate diagnosis and individualized treatment of tumors. This article reviews the research progress of molecular diagnosis and individualized treatment of different lymphoma subtypes and lymphoma-related research in important meetings such as ASCO, EHA, and ICML in 2023.

  • Competing interests: The authors declare that they have no competing interests.

  • [1]
    Wang HW, Balakrishna JP, Pittaluga S, et al. Diagnosis of Hodgkin lymphoma in the modern era[J]. Br J Haematol, 2019, 184(1): 45-59. doi: 10.1111/bjh.15614
    [2]
    Connors JM, Cozen W, Steidl C, et al. Hodgkin lymphoma[J]. Nat Rev Dis Primers, 2020, 6(1): 61. doi: 10.1038/s41572-020-0189-6
    [3]
    Meyer RM, Gospodarowicz MK, Connors JM, et al. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma[J]. N Engl J Med, 2012, 366(5): 399-408. doi: 10.1056/NEJMoa1111961
    [4]
    Abramson JS, Arnason JE, LaCasce AS, et al. Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma[J]. Blood, 2019, 134(7): 606-613. doi: 10.1182/blood.2019001272
    [5]
    Bröckelmann PJ, Goergen H, Keller U, et al. Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial[J]. JAMA Oncol, 2020, 6(6): 872-880. doi: 10.1001/jamaoncol.2020.0750
    [6]
    Allen PB, Savas H, Evens AM, et al. Pembrolizumab followed by AVD in untreated early unfavorable and advanced-stage classical Hodgkin lymphoma[J]. Blood, 2021, 137(10): 1318-1326. doi: 10.1182/blood.2020007400
    [7]
    Park SI, Shea TC, Olajide O, et al. ABVD followed by BV consolidation in risk-stratified patients with limited-stage Hodgkin lymphoma[J]. Blood Adv, 2020, 4(11): 2548-2555. doi: 10.1182/bloodadvances.2020001871
    [8]
    Straus D, Radford J, Connors J, et al. HL-507 First-Line Brentuximab Vedotin Plus Chemotherapy Improves Overall Survival in Patients With Stage Ⅲ/Ⅳ Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1[J]. Clin Lymphoma Myeloma Leuk, 2022, 22(suppl 2): S350.
    [9]
    Herrera AF, LeBlanc ML, Castellino SM, et al. SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage(AS) classic Hodgkin lymphoma(HL)[J]. J Clin Oncol, 2023, 41(suppl 17): LBA4.
    [10]
    Ramchandren R, Domingo-Domènech E, Rueda A, et al. Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase Ⅱ CheckMate 205 Study[J]. J Clin Oncol, 2019, 37(23): 1997-2007. doi: 10.1200/JCO.19.00315
    [11]
    Yang Y, Yang H, Sun P, et al. Smart Start with Tislelizumab as the Front-line Treatment in Patients with High-risk Stage IIB and Advanced-stage Classical Hodgkin Lymphoma [J]. Hematol Oncol, 2023, 41(suppl 2): 114-115.
    [12]
    Evens AM, Advani RH, Helenowski IB, et al. Multicenter Phase Ⅱ Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma[J]. J Clin Oncol, 2018, 36(30): 3015-3022. doi: 10.1200/JCO.2018.79.0139
    [13]
    Cheson BD, Bartlett NL, Laplant B, et al. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial[J]. Lancet Haematol, 2020, 7(11): e808-e815. doi: 10.1016/S2352-3026(20)30275-1
    [14]
    Ansell SM. Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management[J]. Am J Hematol, 2018, 93(5): 704-715. doi: 10.1002/ajh.25071
    [15]
    Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial [J]. Lancet, 2015, 385(9980): 1853-1862. doi: 10.1016/S0140-6736(15)60165-9
    [16]
    Armand P, Chen YB, Redd RA, et al. PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation [J]. Blood, 2019, 134(1): 22-29. doi: 10.1182/blood.2019000215
    [17]
    Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase Ⅱ study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma[J]. J Clin Oncol, 2012, 30(18): 2183-2189. doi: 10.1200/JCO.2011.38.0410
    [18]
    Armand P, Engert A, Younes A, et al. Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase Ⅱ CheckMate 205 Trial [J]. J Clin Oncol, 2018, 36(14): 1428-1439. doi: 10.1200/JCO.2017.76.0793
    [19]
    Kuruvilla J, Ramchandren R, Santoro A, et al. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study[J]. Lancet Oncol, 2021, 22(4): 512-524. doi: 10.1016/S1470-2045(21)00005-X
    [20]
    Zhang HL, Yu JW, Li H. S216: CD47/PD-L1 bispecific antibody (IBI322) in anti-PD-1 or PD-L1 treatment-resistant classical Hodgkin lymphoma: A phase Ⅰ study[J]. Hemasphere, 2023, 7(suppl 3): e8102841.
    [21]
    Zhang L, Li C, Marhaba A, et al. ITF2357 induces cell cycle arrest and apoptosis of meningioma cells via the PI3K-Akt pathway[J]. Med Oncol, 2022, 40(1): 21. doi: 10.1007/s12032-022-01883-w
    [22]
    Li Z, Mu W, Xiao M. Genetic lesions and targeted therapy in Hodgkin lymphoma[J]. Ther Adv Hematol, 2023, 14: 20406207221149245.
    [23]
    Pasqualucci L, Dalla-Favera R. Genetics of diffuse large B-cell lymphoma[J]. Blood, 2018, 131(21): 2307-2319. doi: 10.1182/blood-2017-11-764332
    [24]
    Perry AM, Diebold J, Nathwani BN, et al. Non-Hodgkin lymphoma in the Far East: review of 730 cases from the international non-Hodgkin lymphoma classification project[J]. Ann Hematol, 2016, 95(2): 245-251. doi: 10.1007/s00277-015-2543-4
    [25]
    Wright GW, Huang DW, Phelan JD, et al. A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications[J]. Cancer Cell, 2020, 37(4): 551-568. e14. doi: 10.1016/j.ccell.2020.03.015
    [26]
    Schmitz R, Wright GW, Huang DW, et al. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma[J]. N Engl J Med, 2018, 378(15): 1396-1407. doi: 10.1056/NEJMoa1801445
    [27]
    Zhang H, Lu Y, Zhang T, et al. PIM1 genetic alterations associated with distinct molecular profiles, phenotypes and drug responses in diffuse large B-cell lymphoma[J]. Clin Transl Med, 2022, 12(4): e808. doi: 10.1002/ctm2.808
    [28]
    Zhang T, Lu Y, Liu X, et al. Comprehensive analysis of TP53 mutation characteristics and identification of patients with inferior prognosis and enhanced immune escape in diffuse large B-cell lymphoma[J]. Am J Hematol, 2022, 97(1): E14-E17.
    [29]
    Poeschel V, Held G, Ziepert M, et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial[J]. Lancet, 2019, 394(10216): 2271-2281. doi: 10.1016/S0140-6736(19)33008-9
    [30]
    Lenz G, Tilly H, Ziepert M, et al. Pola-R-CHP versus R-CHOEP in young patients with high-risk diffuse large B-cell lymphoma[J]. Hematol Oncol, 2023, 41(suppl 2): 420-421.
    [31]
    Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma[J]. N Engl J Med, 2022, 386(4): 351-363. doi: 10.1056/NEJMoa2115304
    [32]
    Dunleavy K, Fanale MA, Abramson JS, et al. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study[J]. Lancet Haematol, 2018, 5(12): e609-e617. doi: 10.1016/S2352-3026(18)30177-7
    [33]
    Howlett C, Snedecor SJ, Landsburg DJ, et al. Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis[J]. Br J Haematol, 2015, 170(4): 504-514. doi: 10.1111/bjh.13463
    [34]
    Minson A, Verner E, Giri P, et al. Glofitamab plus R-CHOP or polatuzumab vedotin-R-CHP is deliverable with high overall response in patients ≤65 years of age with high-risk DLBCL: Interim analysis of COALITION[J]. Hematol Oncol, 2023, 41(suppl 2): 421-422.
    [35]
    Rutherford SC, Abramson JS, Bartlett NL, et al. Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study[J]. Lancet Haematol, 2021, 8(11): e818-e827. doi: 10.1016/S2352-3026(21)00273-8
    [36]
    Neelapu SS, Dickinson M, Munoz J, et al. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial [J]. Nat Med, 2022, 28(4): 735-742. doi: 10.1038/s41591-022-01731-4
    [37]
    Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial[J]. Lancet Oncol, 2011, 12(5): 460-468. doi: 10.1016/S1470-2045(11)70069-9
    [38]
    Oberic L, Peyrade F, Puyade M, et al. Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older[J]. J Clin Oncol, 2021, 39(11): 1203-1213. doi: 10.1200/JCO.20.02666
    [39]
    Fields PA, Townsend W, Webb A, et al. De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial[J]. J Clin Oncol, 2014, 32(4): 282-287. doi: 10.1200/JCO.2013.49.7586
    [40]
    Moccia AA, Schaff K, Freeman C, et al. Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines[J]. Blood Adv, 2021, 5(5): 1483-1489. doi: 10.1182/bloodadvances.2020002982
    [41]
    Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma [J]. N Engl J Med, 1995, 333(23): 1540-1545. doi: 10.1056/NEJM199512073332305
    [42]
    Kamdar M, Solomon SR, Arnason J, et al. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial[J]. Lancet, 2022, 399(10343): 2294-2308. doi: 10.1016/S0140-6736(22)00662-6
    [43]
    Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma [J]. N Engl J Med, 2022, 386(7): 640-654. doi: 10.1056/NEJMoa2116133
    [44]
    Zhang HL, Cheng Y, Yang HY, et al. First interim analysis of a phase 1 study of zanubrutinib (zanu) plus lenalidomide (len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)[J]. J Clin Oncol, 2023, 41(suppl 16): 7557.
    [45]
    Kalakonda N, Maerevoet M, Cavallo F, et al. Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial[J]. Lancet Haematol, 2020, 7(7): e511-e522. doi: 10.1016/S2352-3026(20)30120-4
    [46]
    Salles G, Duell J, González Barca E, et al. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study[J]. Lancet Oncol, 2020, 21(7): 978-988. doi: 10.1016/S1470-2045(20)30225-4
    [47]
    Duell J, Maddocks KJ, González-Barca E, et al. Long-term outcomes from the Phase Ⅱ L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma[J]. Haematologica, 2021, 106(9): 2417-2426. doi: 10.3324/haematol.2020.275958
    [48]
    Tan D, Horning SJ, Hoppe RT, et al. Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience[J]. Blood, 2013, 122(6): 981-987. doi: 10.1182/blood-2013-03-491514
    [49]
    Rimsza LM, Li H, Braziel RM, et al. Impact of histological grading on survival in the SWOG S0016 follicular lymphoma cohort [J]. Haematologica, 2018, 103(4): e151-e153. doi: 10.3324/haematol.2017.175059
    [50]
    Koch K, Hoster E, Ziepert M, et al. Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL[J]. Ann Oncol, 2016, 27(7): 1323-1329. doi: 10.1093/annonc/mdw185
    [51]
    Horn H, Kohler C, Witzig R, et al. Gene expression profiling reveals a close relationship between follicular lymphoma grade 3A and 3B, but distinct profiles of follicular lymphoma grade 1 and 2[J]. Haematologica, 2018, 103(7): 1182-1190. doi: 10.3324/haematol.2017.181024
    [52]
    Barraclough A, England JT, Villa D, et al. Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma Alliance[J]. Haematologica, 2023, 108(9): 2444-2453.
    [53]
    Gao F, Zhang T, Liu H, et al. Risk factors for POD24 in patients with previously untreated follicular lymphoma: a systematic review and meta-analysis[J]. Ann Hematol, 2022, 101(11): 2383-2392. doi: 10.1007/s00277-022-04914-8
    [54]
    Gao F, Zhang T, Liu X, et al. Clinical features and outcomes of patients with follicular lymphoma: A real-world study of 926 patients in China[J]. Front Oncol, 2022, 12: 863021. doi: 10.3389/fonc.2022.863021
    [55]
    Lu Y, Yu J, Gong W, et al. An Immune-Clinical Prognostic Index (ICPI) for Patients With De Novo Follicular Lymphoma Treated With R-CHOP/CHOP Chemotherapy[J]. Front Oncol, 2021, 11: 708784. doi: 10.3389/fonc.2021.708784
    [56]
    Lowry L, Smith P, Qian W, et al. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase Ⅲ trial[J]. Radiother Oncol, 2011, 100(1): 86-92. doi: 10.1016/j.radonc.2011.05.013
    [57]
    Macmanus M, Fisher R, Roos D, et al. Randomized Trial of Systemic Therapy After Involved-Field Radiotherapy in Patients With Early-Stage Follicular Lymphoma: TROG 99.03[J]. J Clin Oncol, 2018, 36(29): 2918-2925.
    [58]
    Marcus R, Davies A, Ando K, et al. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma[J]. N Engl J Med, 2017, 377(14): 1331-1344. doi: 10.1056/NEJMoa1614598
    [59]
    Hong X, Song Y, Shi Y, et al. Efficacy and safety of obinutuzumab for the first-line treatment of follicular lymphoma: a subgroup analysis of Chinese patients enrolled in the phase Ⅲ GALLIUM study[J]. Chin Med J (Engl), 2021, 135(4): 433-440.
    [60]
    Hiddemann W, Barbui AM, Canales MA, et al. Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety[J]. J Clin Oncol, 2018, 36(23): 2395-2404. doi: 10.1200/JCO.2017.76.8960
    [61]
    Jacobsen E. Follicular lymphoma: 2023 update on diagnosis and management[J]. Am J Hematol, 2022, 97(12): 1638-1651. doi: 10.1002/ajh.26737
    [62]
    Zucca E, Rondeau S, Vanazzi A, et al. Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy [J]. Blood, 2019, 134(4): 353-362. doi: 10.1182/blood-2018-10-879643
    [63]
    Morschhauser F, Fowler NH, Feugier P, et al. Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma[J]. N Engl J Med, 2018, 379(10): 934-947. doi: 10.1056/NEJMoa1805104
    [64]
    Martin P, Jung SH, Pitcher B, et al. A phase Ⅱ trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance)[J]. Ann Oncol, 2017, 28(11): 2806-2812. doi: 10.1093/annonc/mdx496
    [65]
    Sehn LH, Bartlett NL, Matasar M, et al. Mosunetuzumab demonstrates durable responses in patients with relapsed and/or refractory follicular lymphoma who have received ≥2 prior therapies: updated analysis of a pivotal phase Ⅱ study[J]. Hematol Oncol, 2023, 41(suppl 2): 122-125.
    [66]
    Merryman RW, Belada D, Sureda A, et al. Epcoritamab + R2 regimen and responses in patients with high-risk follicular lymphoma, regardless of POD24 status[J]. Clin Lymphoma Myeloma Leuk, 2023, 23(Suppl 1): S210.
    [67]
    Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. doi: 10.3322/caac.21338
    [68]
    Ferrero S, Rossi D, Rinaldi A, et al. KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study[J]. Haematologica, 2020, 105(6): 1604-1612. doi: 10.3324/haematol.2018.214056
    [69]
    Lv H, Fei Y, Li W, et al. A novel clinical immune-related prognostic model predicts the overall survival of mantle cell lymphoma[J]. Hematol Oncol, 2022, 40(3): 343-355. doi: 10.1002/hon.2994
    [70]
    Wu X, Lu H, Pang T, et al. Association of minimal residual disease levels with clinical outcomes in patients with mantle cell lymphoma: A meta-analysis[J]. Leuk Res, 2021, 108: 106605. doi: 10.1016/j.leukres.2021.106605
    [71]
    Mckay P, Leach M, Jackson B, et al. Guideline for the management of mantle cell lymphoma[J]. Br J Haematol, 2018, 182(1): 46-62. doi: 10.1111/bjh.15283
    [72]
    Sarkozy C, Thieblemont C, Oberic L, et al. Very long-term follow-up of rituximab maintenance in young patients with mantle cell lymphoma included in the lyma trial, a lysa study[J]. Hematol Oncol, 2023, 41(suppl 2): 151-152.
    [73]
    Wang ML, Jain P, Zhao S, et al. Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial[J]. Lancet Oncol, 2022, 23(3): 406-415. doi: 10.1016/S1470-2045(21)00638-0
    [74]
    Wang M, Jain P, Lee HJ, et al. Ibrutinib Plus Rituximab and Venetoclax (IRV) Followed By Risk-Stratified Observation or Short Course R-Hypercvad/MTX in Young Patients with Previously Untreated Mantle Cell Lymphoma- Phase-Ⅱ Window-2 Clinical Trial[J]. Blood, 2021, 138(suppl 1): 3525.
    [75]
    Wang ML, Lee HJ, Fetooh A, et al. Ibrutinib-rituximab and venetoclax (IRV) followed by risk-stratified R-HyperCVAD/MTX in young patients with untreated mantle cell lymphoma-phase-Ⅱ WINDOW-2 trial[J]. Hematol Oncol, 2023, 41(suppl 2): 152-153.
    [76]
    Dreyling M, Doorduijn JK, Gine E, et al. Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network[J]. Blood, 2022, 140(suppl 1): 1-3.
    [77]
    Jain P, Zhao S, Lee HJ, et al. Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma[J]. J Clin Oncol, 2022, 40(2): 202-212. doi: 10.1200/JCO.21.01797
    [78]
    Wang M, Jurczak W, Jerkeman M, et al. Primary results from the double-blind, placebo-controlled, phase Ⅲ SHINE study of ibrutinib in combination with bendamustine-rituximab (BR) and R maintenance as a first-line treatment for older patients with mantle cell lymphoma (MCL)[J]. J Clin Oncol, 2022, 40(suppl 17): LBA7502.
    [79]
    Cohen JB, Shah NN, Alencar AJ, et al. MCL-133 Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Previously Treated Mantle Cell Lymphoma: Updated Results From the Phase 1/2 BRUIN Study[J]. Clin Lymphoma Myeloma Leuk, 2022, 22 Suppl 2: S394-S395.
    [80]
    Wang M, Munoz J, Goy A, et al. Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study[J]. J Clin Oncol, 2023, 41(3): 555-567. doi: 10.1200/JCO.21.02370
    [81]
    Toby A, Eyre CY, Wang ML. Therapeutic options for relapsed/refractory mantle cell lymphoma[J]. Blood, 2022, 139(5): 666-667. doi: 10.1182/blood.2021013326
    [82]
    Wilson MR, Barrett A, Cheah CY, et al. How I manage mantle cell lymphoma: indolent versus aggressive disease[J]. Br J Haematol, 2023, 201(2): 185-198. doi: 10.1111/bjh.18697
    [83]
    Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes[J]. J Clin Oncol, 2008, 26(25): 4124-4130. doi: 10.1200/JCO.2008.16.4558
    [84]
    Iqbal J, Wright G, Wang C, et al. Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma[J]. Blood, 2014, 123(19): 2915-2923. doi: 10.1182/blood-2013-11-536359
    [85]
    Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms[J]. Leukemia, 2022, 36(7): 1720-1748. doi: 10.1038/s41375-022-01620-2
    [86]
    Marchi E, O'Connor OA. The rapidly changing landscape in mature T-cell lymphoma (MTCL) biology and management[J]. CA Cancer J Clin, 2020, 70(1): 47-70. doi: 10.3322/caac.21589
    [87]
    Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J]. Blood, 2016, 127(20): 2375-2390. doi: 10.1182/blood-2016-01-643569
    [88]
    Cai QQ, Zhu J, Song Y, et al. Golidocitinib in treating refractory or relapsed peripheral T-cell lymphoma: Primary analysis of the multinational pivotal study results (JACKPOT8)[J]. J Clin Oncol, 2023, 41(suppl 16): 7503.
    [89]
    Horwitz SM, Koch R, Porcu P, et al. Activity of the PI3K-δ, γ inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma[J]. Blood, 2018, 131(8): 888-898. doi: 10.1182/blood-2017-08-802470
    [90]
    Zaja F, Tabanelli V, Agostinelli C, et al. CD38, BCL-2, PD-1, and PD-1L expression in nodal peripheral T-cell lymphoma: Possible biomarkers for novel targeted therapies? [J]. Am J Hematol, 2017, 92(1): E1-E2. doi: 10.1002/ajh.24502
    [91]
    Rassidakis GZ, Jones D, Lai R, et al. BCL-2 family proteins in peripheral T-cell lymphomas: correlation with tumour apoptosis and proliferation[J]. J Pathol, 2003, 200(2): 240-248. doi: 10.1002/path.1346
    [92]
    Piccaluga PP, Agostinelli C, Righi S, et al. Expression of CD52 in peripheral T-cell lymphoma[J]. Haematologica, 2007, 92(4): 566-567. doi: 10.3324/haematol.10767
    [93]
    Lindauer M, Hochhaus A. Dasatinib[J]. Recent Results Cancer Res, 2014, 201: 27-65.
    [94]
    Laimer D, Dolznig H, Kollmann K, et al. PDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas[J]. Nat Med, 2012, 18(11): 1699-1704. doi: 10.1038/nm.2966
    [95]
    Piccaluga PP, Rossi M, Agostinelli C, et al. Platelet-derived growth factor alpha mediates the proliferation of peripheral T-cell lymphoma cells via an autocrine regulatory pathway[J]. Leukemia, 2014, 28(8): 1687-1697. doi: 10.1038/leu.2014.50
    [96]
    Barta SK, Zain J, Macfarlane AW, et al. Phase Ⅱ Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma[J]. Clin Lymphoma Myeloma Leuk, 2019, 19(6): 356-364. e3. doi: 10.1016/j.clml.2019.03.022
    [97]
    Bennani NN, Kim HJ, Pederson LD, et al. Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression[J]. J Immunother Cancer, 2022, 10(6): e004984. doi: 10.1136/jitc-2022-004984
  • Related Articles

    [1]DUAN Xiaoyang, SHI Jian. Research Status and Progress on Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma in Hebei Province[J]. Cancer Research on Prevention and Treatment, 2025, 52(2): 103-109. DOI: 10.3971/j.issn.1000-8578.2025.24.0856
    [2]HAN Jing, CHEN Yarui, WANG Song, GUAN Quanlin. Research Progress of Antibody-drug Conjugates in Small-cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2023, 50(11): 1139-1144. DOI: 10.3971/j.issn.1000-8578.2023.23.0447
    [3]WANG Tianming, ZHANG Liang, CHENG Ying. Progress of Research on Immune-related Pneumonia in Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2023, 50(8): 808-812. DOI: 10.3971/j.issn.1000-8578.2023.23.0075
    [4]CHENG Ying. Research Progress of Immunotherapy for Advanced Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2021, 48(8): 745-750. DOI: 10.3971/j.issn.1000-8578.2021.21.0472
    [5]LI Xiaofen, YUAN Ying. Individualized Treatment for Advanced Colorectal Cancer Patients Based on Molecular Characteristics[J]. Cancer Research on Prevention and Treatment, 2015, 42(09): 924-928. DOI: 10.3971/j.issn.1000-8578.2015.09.014
    [6]ZHANG Yanli, ZHU Shunqin, LIU Yaling, CUI Hongjuan. 恶性黑色素瘤内科治疗研究进展[J]. Cancer Research on Prevention and Treatment, 2014, 41(01): 74-78. DOI: 10.3971/j.issn.1000-8578.2014.01.017

Catalog

    Article views (2094) PDF downloads (2175) Cited by()

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return